Lantus is a brand name for insulin glargine, a long-acting insulin used to manage blood sugar levels in adults and children with type 1 and type 2 diabetes [1]. It works by mimicking the action of naturally occurring insulin, providing a basal (background) level of insulin for about 24 hours [2].
How Does Lantus Work for Diabetes Management?
Lantus is a recombinant human insulin analog that is slowly released into the bloodstream after injection [3]. This sustained release helps to keep blood glucose levels stable between meals and overnight, reducing the risk of hyperglycemia [2]. Unlike rapid-acting insulins that are taken before meals, Lantus is typically injected once daily, providing a consistent baseline of insulin activity [1].
When Does Lantus Patent Protection Expire?
The patents for Lantus have largely expired in major markets, leading to the availability of generic versions [4]. For instance, the primary patents for Lantus expired in the United States around 2015 and in Europe in 2020 [5][6]. This has opened the door for biosimilar competition.
What Are the Generic Alternatives to Lantus?
Following patent expiries, biosimilar versions of insulin glargine have become available. These biosimilars are highly similar to Lantus in terms of safety, purity, and potency, and are approved by regulatory agencies to be interchangeable with the reference product [7]. Examples of biosimilars include Basaglar (Eli Lilly) and Semglee (Viatris, formerly Mylan) [8][9].
How Do Lantus and Its Biosimilars Compare to Other Long-Acting Insulins?
Lantus and its biosimilars are classified as long-acting insulins. They offer a duration of action of approximately 24 hours, suitable for basal insulin therapy. Other long-acting insulins include insulin detemir (Levemir) and insulin degludec (Tresiba), which also provide basal coverage but may differ in their duration of action, onset, and peakless profiles [10]. For example, insulin degludec can provide coverage for over 42 hours in some individuals [10].
What Are the Risks and Side Effects Associated with Lantus?
The primary risk associated with Lantus, like all insulins, is hypoglycemia (low blood sugar) [2]. Symptoms of hypoglycemia can include shakiness, sweating, dizziness, confusion, and rapid heart rate. Other potential side effects include injection site reactions, such as redness, swelling, or itching, and lipodystrophy (changes in fat tissue at the injection site) [1].
How is Lantus Dosing and Administration Handled?
Lantus is administered via subcutaneous injection, typically once daily at the same time each day [1]. The dosage is individualized based on the patient's blood glucose levels, diet, activity level, and other medications. It is crucial for patients to follow their healthcare provider's instructions regarding dosage and administration [2].
Sources:
[1] https://www.lantus.com/
[2] https://www.webmd.com/drugs/2d7368/lantus-insulin-glargine-subcutaneous-injection/details
[3] https://www.drugs.com/lantus.html
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/drug/insulin-glargine
[6] https://www.fiercepharma.com/patent/sanofi-loses-key-lantus-patent-challenge-us
[7] https://www.fda.gov/drugs/biosimilars/what-biosimilar-and-interchangeable-biosimilar
[8] https://www.drugpatentwatch.com/drug/basaglar
[9] https://www.drugpatentwatch.com/drug/semglee
[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714806/